ROVI Rebrands as ROIS, Acquires U.S. Injectable Manufacturing Site

ROVI’s Contract Development and Manufacturing Organization (CDMO) business unit will rebrand as ROIS and acquire a sterile injectable drug product manufacturing facility in Phoenix, Arizona from Bristol Myers Squibb. The move marks a significant expansion of the company’s global footprint and manufacturing capabilities, positioning ROIS as a transatlantic CDMO with direct U.S. production capacity.

The Phoenix site spans approximately 34,000 square meters on an 80,000 square meter campus and has received over $100 million in capital investment since 2021. It includes a cytotoxic/high-potent (OEB5) area and holds regulatory approvals from the U.S. Food and Drug Administration, European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency. ROIS plans to install an Optima pre-filled syringe (PFS) isolator line by 2027, which is expected to add 65–70 million units of annual PFS capacity.

The company said the expansion will increase global capacity and flexibility, provide direct U.S.-based manufacturing for pharmaceutical and biotech clients, and reinforce its commitment to innovation.

“This acquisition is a strategic step in building ROIS as a global CDMO for high-value injectables,” said Javier López-Belmonte, Vice Chairman of the Board and Chief Financial Officer. “The Phoenix site adds significant sterile fill-finish and high-potent capability, enabling us to better serve partners on U.S. soil while continuing to invest across our network.”

The rebrand to ROIS reflects the company’s broader ambitions and ongoing investment in technology, infrastructure, and service offerings. ROIS has built a reputation in Europe for injectable development and manufacturing, and the new identity signals its intent to become a global partner of choice.

“Our transformation into ROIS reflects where we are today and where we are headed,” López-Belmonte said. “We are proud of our legacy and excited about our future — growing, investing, and expanding capacity to meet our partners’ needs worldwide.”

Other Pharma Industry Acquisitions 

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.